Research Analysts’ Recent Ratings Changes for Novavax (NVAX)

Several brokerages have updated their recommendations and price targets on shares of Novavax (NASDAQ: NVAX) in the last few weeks:

• 3/12/2026 – Novavax was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 3/12/2026 – Novavax had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 2/28/2026 – Novavax was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/27/2026 – Novavax had its price target raised by HC Wainwright from $11.00 to $16.00. They now have a “buy” rating on the stock.
• 1/31/2026 – Novavax was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/23/2026 – Novavax was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/20/2026 – Novavax had its “buy” rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.